Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Revenue (2020 - 2025)

Ovid Therapeutics' Revenue history spans 6 years, with the latest figure at $718000.0 for Q4 2025.

  • For Q4 2025, Revenue changed N/A year-over-year to $718000.0; the TTM value through Dec 2025 reached $7.3 million, up 1380.0%, while the annual FY2025 figure was $7.3 million, 1181.27% up from the prior year.
  • Revenue reached $718000.0 in Q4 2025 per OVID's latest filing, up from $132000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $222.8 million in Q4 2023 to a low of $11102.0 in Q3 2022.
  • Average Revenue over 5 years is $55.2 million, with a median of $171000.0 recorded in 2024.
  • Peak YoY movement for Revenue: soared 3775.03% in 2021, then plummeted 99.57% in 2022.
  • A 5-year view of Revenue shows it stood at $221.0 million in 2021, then increased by 0.68% to $222.5 million in 2022, then grew by 0.13% to $222.8 million in 2023, then crashed by 99.92% to $173000.0 in 2024, then surged by 315.03% to $718000.0 in 2025.
  • Per Business Quant, the three most recent readings for OVID's Revenue are $718000.0 (Q4 2025), $132000.0 (Q3 2025), and $6.3 million (Q2 2025).